计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Idarubicin HCl是Idarubicin的盐酸盐形式,是蒽环类抗生素,抑制DNA拓扑异构酶II (topo II),作用于MCF-7细胞,IC50为3.3 ng/mL。An apoptosis inducer.
Information
Idarubicin HCl (4-demethoxydaunorubicin, NSC256439, 4-DMDR) is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and aDNA topoisomerase II (topo II)inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay. Idarubici
In vitro
Idarubicin has significant cytotoxic activity against multicellular spheroids, comparable to the antiproliferative effects on monolayer cells. Idarubicin inhibits CYP450 2D6. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively. Idarubicin is able to overcome P-glycoprotein-mediated multidrug resistance. Idarubicin inhibits PMN superoxide radical formation. Idarubicin could be coupled to the monoclonal antibodies (anti-Ly-2.1, anti-L3T4, or anti-Thy-1) with retention of protein solubility and antibody activity. Idarubicin inhibits the proliferation of NALM-6 cells with an IC50 of 12 nM.
In vivo
Reduction of Idarubicin is dependent upon ketone reductases, and proceeds more stereoselectively than that of most ketones giving rise to the (13S)-epimer almost exclusively. The high stereospecificity in Idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in Idarubicin.
Cell Data
cell lines:
Concentrations:0.1 nM-10 μM
Incubation Time:24 hours
Powder Purity:≥99%
H341: 怀疑引起遗传缺陷
H351: 怀疑引起遗传缺陷
H300: 吞咽致命
H360: 可能损害生育力或未出生的孩子
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P321: 特殊处理(请参阅此标签上的...)。
P405: 密闭存放
P501: 将内容物/容器处理到。。。
P264: 处理后要彻底洗手。
P281: 根据需要使用个人防护设备。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P330: 漱口
P203: 使用前,获取、阅读并遵守所有安全说明。
P301+P316: 如果吞咽:立即寻求紧急医疗救助。
P318: 如果暴露或担心,请就医。